Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus HYPAQUE M 90.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus HYPAQUE M 90.
HYPAQUE-CYSTO vs HYPAQUE-M,90%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent